Mayne Pharma GroupMAYNF 43 Days Payable is 273.42 as of Dec. 2025, which is 230% above its 10-year median of 82.81. GuruFocus rates MAYNF with a GF Score™ of 43/100 and a GF Value™ of $3.41 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 115 Medical Distribution companies, Mayne Pharma Group ranks better than 95.65% on this metric.
The historical rank and industry rank for Mayne Pharma Group's Days Payable or its related term are showing as below:
MAYNF'
s Days Payable Range Over the Past 10 Years
Min: 56.92 Med: 82.81 Max: 345.17
Current: 336.69
During the past 13 years, Mayne Pharma Group's highest Days Payable was 345.17. The lowest was 56.92. And the median was 82.81.
MAYNF's Days Payable is ranked better than 95.65% of 115
companies
in the Medical Distribution industry
Industry Median: 79.81
vs MAYNF: 336.69
Mayne Pharma Group's Days Payable
increased
from Dec. 2024 (246.47) to Dec. 2025 (273.42).
It may suggest that Mayne Pharma Groupdelayed paying its suppliers.
Mayne Pharma Group Days Payable Related Terms
Mayne Pharma Group Days Payable Historical Data
* Premium members only.
The historical data trend for Mayne Pharma Group's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Mayne Pharma Group's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mayne Pharma Group Days Payable vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Mayne Pharma Group's Days Payable distribution charts can be found below:
* The bar in red indicates where Mayne Pharma Group's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Mayne Pharma Group's Days Payable for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mayne Pharma Group (MAYNF) has a Days Payable of 273.42 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Mayne Pharma Group and its competitors. This is 230% above median its historical median of 82.81. Over the past decade, Mayne Pharma Group's Days Payable has ranged from 56.92 to 345.17. According to the industry distribution chart, Mayne Pharma Group ranks #5 out of 115 companies in the Medical Distribution industry, placing it in the top 4.3%.
Is Mayne Pharma Group's Days Payable too high?
Mayne Pharma Group's current Days Payable of 273.42 is 230% above median its 10-year median of 82.81. Over the past 10 years, this metric has ranged from a low of 56.92 to a high of 345.17. The Medical Distribution industry median Days Payable is 79.81. Mayne Pharma Group's value of 273.42 is 242.6% above this industry median. Based on the distribution chart, Mayne Pharma Group ranks #5 out of 115 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Mayne Pharma Group has a GF Score™ of 43/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Mayne Pharma Group's Days Payable compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Mayne Pharma Group ranks #5 out of 115 companies for Days Payable. This places Mayne Pharma Group in the top 4% of its industry — outperforming the majority of peers. The industry median Days Payable is 79.81. Mayne Pharma Group's value of 273.42 is 242.6% above this benchmark. Historically, Mayne Pharma Group's own Days Payable has ranged from 56.92 to 345.17 over the past decade. While the company's 10-year median is 82.81 vs. the industry median of 79.81, Mayne Pharma Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Distribution company?
The median Days Payable among Medical Distribution companies is 79.81, based on 115 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mayne Pharma Group's current Days Payable of 273.42 is 242.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Mayne Pharma Group and its competitors. For the Medical Distribution industry, the median Days Payable is 79.81 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mayne Pharma Group's current Days Payable is 273.42, which is 230% above median its own 10-year median of 82.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mayne Pharma Group stock overvalued right now?
Based on GuruFocus' analysis, Mayne Pharma Group (MAYNF) is currently considered Possible Value Trap. The stock's GF Value™ is $3.41, compared to a current price of $1.65 — trading 51.6% below its estimated fair value. The current Days Payable is 273.42, which is 230% above median its 10-year median of 82.81 and 242.6% above the Medical Distribution industry median of 79.81. Mayne Pharma Group's overall GF Score™ is 43/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Mayne Pharma Group (MAYNF), the current Days Payable is 273.42 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mayne Pharma Group (MAYNF) Overvalued in 2026?
Based on GuruFocus' analysis, Mayne Pharma Group stock appears to be undervalued.
The current stock price of $1.65 is trading 51.6% below its estimated GF Value™ of $3.41.
GuruFocus considers Mayne Pharma Group to be Possible Value Trap.
Key valuation signals for MAYNF:
Days Payable: 273.42 (230% above median its 10-year median of 82.81)
GF Value™: $3.41 vs. price of $1.65 (51.6% below fair value)
Industry Position: 242.6% above the Medical Distribution median (#5 of 115)
No single metric tells the full story. See the MAYNF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mayne Pharma Group Ltd is a specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals It has a Forty-year track record of innovation and success in developing oral drug delivery systems. The Company's Business consists of three operating segments being International, Women's Health and Dermatology. The Dermatologysegment distributes dermatology products (branded and generic) in the U.S. on a portfolio basis, The Women's Health segment distributes branded women's health products in the U.S. International's segment revenue and gross profit are derived principally from the Australian manufacture and sale of branded and generic pharmaceutical products.
43GF Score
Get the complete analysis for MAYNF
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MAYNF has been successfully added to your 
